Published in Biotech Business Week, August 11th, 2008
"Ages, gender, diagnosis, disease status and treatment variables were equally distributed between groups. Survival on D + 180 was increased in GlPN (74%) vs PN (46%), P = 0.03 (log-rank), as on D + 100 (P = 0.05). Most deaths occurred before...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.